 |
1 Disease |  |
53 Trials |
|
53 Trials |  |
581 News |  |
| «123456789 |
- || Inqovi (decitabine/cedazuridine) / Otsuka
Trial completion date, Trial primary completion date: ASTX727-03: Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS (clinicaltrials.gov) - Jul 5, 2019
P1/2, N=122, Recruiting, Sponsor: Astex Pharmaceuticals
Trial completion date: Jun 2020 --> Dec 2020 | Trial primary completion date: Jun 2019 --> Dec 2020
- || Inqovi (decitabine/cedazuridine) / Otsuka
Enrollment closed: Effect of Food on Blood Levels of ASTX727 (clinicaltrials.gov) - Jun 12, 2019
P1b, N=18, Active, not recruiting, Sponsor: Astex Pharmaceuticals
Trial completion date: Jun 2020 --> Dec 2020 | Trial primary completion date: Jun 2019 --> Dec 2020 Recruiting --> Active, not recruiting
- || Inqovi (decitabine/cedazuridine) / Otsuka
Trial completion date, Trial primary completion date: Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Jun 12, 2019
P1/2, N=113, Active, not recruiting, Sponsor: Astex Pharmaceuticals
Recruiting --> Active, not recruiting Trial completion date: Jun 2019 --> Sep 2019 | Trial primary completion date: Jun 2019 --> Sep 2019
- || eltanexor (KPT-8602) / Ono Pharma, Karyopharm
Trial completion date, Trial primary completion date: KCP-8602-801: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications (clinicaltrials.gov) - May 10, 2019
P1/2, N=119, Recruiting, Sponsor: Karyopharm Therapeutics Inc
Trial completion date: Jun 2019 --> Sep 2019 | Trial primary completion date: Jun 2019 --> Sep 2019 Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Mar 2019 --> Mar 2020
- || Inqovi (decitabine/cedazuridine) / Otsuka
New P1 trial: ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas (clinicaltrials.gov) - Apr 21, 2019
P1, N=18, Not yet recruiting, Sponsor: Massachusetts General Hospital
- || decitabine / Generic mfg.
Enrollment open: Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors (clinicaltrials.gov) - Apr 18, 2019
P1, N=30, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Mar 2019 --> Mar 2020 Not yet recruiting --> Recruiting
- || Inqovi (decitabine/cedazuridine) / Otsuka
New P1 trial: Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes (clinicaltrials.gov) - Apr 8, 2019
P1, N=30, Recruiting, Sponsor: Otsuka Pharmaceutical Co., Ltd.
- || decitabine / Generic mfg.
New P1 trial: Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors (clinicaltrials.gov) - Mar 13, 2019
P1, N=30, Not yet recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- |||| Inqovi (decitabine/cedazuridine) / Otsuka
Enrollment closed, Trial completion date, Trial primary completion date: Ascertain: Study of ASTX727 vs IV Decitabine in MDS, CMML, and AML (clinicaltrials.gov) - Feb 8, 2019
P3, N=132, Active, not recruiting, Sponsor: Astex Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Jun 2019 --> May 2020 | Trial primary completion date: Dec 2018 --> Jun 2019
- || Inqovi (decitabine/cedazuridine) / Otsuka
New P1 trial: Effect of Food on Blood Levels of ASTX727 (clinicaltrials.gov) - Jan 23, 2019
P1b, N=18, Recruiting, Sponsor: Astex Pharmaceuticals
- | Journal, PD(L)-1 Biomarker, IO biomarker: Therapeutic choices after hypomethylating agent resistance for myelodysplastic syndromes. (Pubmed Central) - Jan 13, 2019
Recruiting --> Active, not recruiting | Trial completion date: Jun 2019 --> May 2020 | Trial primary completion date: Dec 2018 --> Jun 2019 Despite the poor prognosis associated with HMA failure, clinical trials, new cytotoxic agents and allogeneic stem-cell transplantation, can offer therapeutic opportunities for these patients for whom there is no standard of care.
- || Inqovi (decitabine/cedazuridine) / Otsuka
Trial completion date, Trial primary completion date: Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Jan 9, 2019
P1/2, N=113, Active, not recruiting, Sponsor: Astex Pharmaceuticals
Despite the poor prognosis associated with HMA failure, clinical trials, new cytotoxic agents and allogeneic stem-cell transplantation, can offer therapeutic opportunities for these patients for whom there is no standard of care. Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2018 --> Jun 2019
- | Keytruda (pembrolizumab) / Merck (MSD), guadecitabine (SGI-110) / Otsuka, Inqovi (decitabine/cedazuridine) / Otsuka
Enrollment open, Trial primary completion date, Combination therapy: HyPeR: Combination Study of Guadecitabine/ASTX727 and Pembrolizumab (clinicaltrials.gov) - Oct 18, 2018
P1, N=35, Recruiting, Sponsor: Royal Marsden NHS Foundation Trust
Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2018 --> Jun 2019 Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2018 --> Dec 2019
- | eltanexor (KPT-8602) / Ono Pharma, Karyopharm
Trial completion date, Trial primary completion date: KCP-8602-801: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications (clinicaltrials.gov) - Oct 16, 2018
P1/2, N=119, Recruiting, Sponsor: Karyopharm Therapeutics Inc
Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2018 --> Dec 2019 Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Sep 2018 --> Mar 2019
- | Venclexta (venetoclax) / Roche, AbbVie
Enrollment open, Combination therapy: Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN (clinicaltrials.gov) - Oct 9, 2018
P1, N=38, Recruiting, Sponsor: Jacqueline Garcia, MD
Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Sep 2018 --> Mar 2019 Not yet recruiting --> Recruiting
- | Inqovi (decitabine/cedazuridine) / Otsuka
Enrollment open: ASTX727-03: Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS (clinicaltrials.gov) - Aug 6, 2018
P1/2, N=122, Recruiting, Sponsor: Astex Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Venclexta (venetoclax) / Roche, AbbVie
New P1 trial, Combination therapy: Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN (clinicaltrials.gov) - Aug 3, 2018
P1, N=38, Not yet recruiting, Sponsor: Jacqueline Garcia, MD
- | eltanexor (KPT-8602) / Ono Pharma, Karyopharm
Trial primary completion date: KCP-8602-801: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications (clinicaltrials.gov) - Jul 19, 2018
P1/2, N=103, Recruiting, Sponsor: Karyopharm Therapeutics Inc
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2018 --> Sep 2018
- ||||| Inqovi (decitabine/cedazuridine) / Otsuka
New P1/2 trial: ASTX727-03: Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS (clinicaltrials.gov) - Apr 18, 2018
P1/2, N=122, Not yet recruiting, Sponsor: Astex Pharmaceuticals
- || Inqovi (decitabine/cedazuridine) / Otsuka
Trial completion date, Trial primary completion date: Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Apr 10, 2018
P1/2, N=113, Active, not recruiting, Sponsor: Astex Pharmaceuticals
Trial primary completion date: Jun 2018 --> Sep 2018 Trial completion date: Mar 2018 --> Dec 2018 | Trial primary completion date: Mar 2018 --> Dec 2018
- |||||| Inqovi (decitabine/cedazuridine) / Otsuka
Enrollment open: Ascertain: Study of ASTX727 vs IV Decitabine in MDS, CMML, and AML (clinicaltrials.gov) - Mar 29, 2018
P3, N=132, Recruiting, Sponsor: Astex Pharmaceuticals
Trial completion date: Mar 2018 --> Dec 2018 | Trial primary completion date: Mar 2018 --> Dec 2018 Not yet recruiting --> Recruiting
- || eltanexor (KPT-8602) / Ono Pharma, Karyopharm
Trial primary completion date: KCP-8602-801: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications (clinicaltrials.gov) - Dec 26, 2017
P1/2, N=103, Recruiting, Sponsor: Karyopharm Therapeutics Inc
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2018 --> Jun 2018
- |||||||||| Inqovi (decitabine/cedazuridine) / Otsuka
New P3 trial: Ascertain: Study of ASTX727 vs IV Decitabine in MDS, CMML, and AML (clinicaltrials.gov) - Oct 10, 2017
P3, N=132, Not yet recruiting, Sponsor: Astex Pharmaceuticals
- ||| Inqovi (decitabine/cedazuridine) / Otsuka
Enrollment closed, Trial primary completion date: Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Aug 29, 2017
P1/2, N=113, Active, not recruiting, Sponsor: Astex Pharmaceuticals
Trial primary completion date: Jan 2018 --> Jun 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Mar 2018
- || eltanexor (KPT-8602) / Ono Pharma, Karyopharm
Trial primary completion date: KCP-8602-801: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications (clinicaltrials.gov) - May 30, 2017
P1/2, N=116, Recruiting, Sponsor: Karyopharm Therapeutics Inc
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Mar 2018 Trial primary completion date: Apr 2017 --> Jan 2018
- |||| Imfinzi (durvalumab) / AstraZeneca, Inqovi (decitabine/cedazuridine) / Otsuka
Enrollment open, Combination therapy, Monotherapy, PD(L)-1 Biomarker, IO biomarker, Metastases: Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients (clinicaltrials.gov) - Mar 22, 2017
P1/2, N=59, Recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Apr 2017 --> Jan 2018 Not yet recruiting --> Recruiting
- || eltanexor (KPT-8602) / Ono Pharma, Karyopharm
Trial primary completion date: KCP-8602-801: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications (clinicaltrials.gov) - Feb 13, 2017
P1/2, N=116, Recruiting, Sponsor: Karyopharm Therapeutics, Inc
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Apr 2017
- ||||| Imfinzi (durvalumab) / AstraZeneca, Inqovi (decitabine/cedazuridine) / Otsuka
New P1/2 trial, Combination therapy, Monotherapy, PD(L)-1 Biomarker, IO biomarker, Metastases: Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients (clinicaltrials.gov) - Jan 12, 2017
P1/2, N=59, Not yet recruiting, Sponsor: Massachusetts General Hospital
- | Keytruda (pembrolizumab) / Merck (MSD), guadecitabine (SGI-110) / Otsuka, Inqovi (decitabine/cedazuridine) / Otsuka
New P1 trial, Combination therapy: HyPeR: Combination Study of Guadecitabine/ASTX727 and Pembrolizumab (clinicaltrials.gov) - Dec 21, 2016
P1, N=35, Not yet recruiting, Sponsor: Royal Marsden NHS Foundation Trust
- |||| Inqovi (decitabine/cedazuridine) / Otsuka
Enrollment open, Enrollment change: Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Nov 18, 2016
P1/2, N=120, Recruiting, Sponsor: Astex Pharmaceuticals
Trial primary completion date: Dec 2016 --> Apr 2017 Active, not recruiting --> Recruiting | N=96 --> 120
- || Inqovi (decitabine/cedazuridine) / Otsuka
Trial primary completion date: Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Sep 20, 2016
P1/2, N=96, Active, not recruiting, Sponsor: Astex Pharmaceuticals
Active, not recruiting --> Recruiting | N=96 --> 120 Trial primary completion date: Sep 2016 --> Apr 2017
- ||| Inqovi (decitabine/cedazuridine) / Otsuka
Enrollment closed, Trial primary completion date: Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Jul 18, 2016
P1/2, N=96, Active, not recruiting, Sponsor: Astex Pharmaceuticals
Trial primary completion date: Sep 2016 --> Apr 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Sep 2016
- |||| eltanexor (KPT-8602) / Ono Pharma, Karyopharm
Enrollment open: KCP-8602-801: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications (clinicaltrials.gov) - Feb 22, 2016
P1/2, N=116, Recruiting, Sponsor: Karyopharm Therapeutics, Inc
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Sep 2016 Active, not recruiting --> Recruiting
- ||||| eltanexor (KPT-8602) / Ono Pharma, Karyopharm
New P1/2 trial: KCP-8602-801: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications (clinicaltrials.gov) - Jan 7, 2016
P1/2, N=116, Active, not recruiting, Sponsor: Karyopharm Therapeutics, Inc
- ||| Inqovi (decitabine/cedazuridine) / Otsuka
Enrollment change, Trial primary completion date: Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Dec 17, 2015
P1/2, N=85, Recruiting, Sponsor: Astex Pharmaceuticals
Active, not recruiting --> Recruiting N=150 --> 85 | Trial primary completion date: Feb 2016 --> Jun 2016
- || Inqovi (decitabine/cedazuridine) / Otsuka
Trial primary completion date: Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Jul 1, 2015
P1/2, N=150, Recruiting, Sponsor: Astex Pharmaceuticals
N=150 --> 85 | Trial primary completion date: Feb 2016 --> Jun 2016 Trial primary completion date: Jun 2015 --> Feb 2016
- |||| Inqovi (decitabine/cedazuridine) / Otsuka
Enrollment open: Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Jul 12, 2014
P1/2, N=150, Recruiting, Sponsor: Astex Pharmaceuticals
Trial primary completion date: Jun 2015 --> Feb 2016 Not yet recruiting --> Recruiting
- ||||| Inqovi (decitabine/cedazuridine) / Otsuka
New P1/2 trial: Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Apr 2, 2014
P1/2, N=150, Not yet recruiting, Sponsor: Astex Pharmaceuticals